Serina Therapeutics, Inc.
SER · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.18 | 0.11 | 1.61 |
| FCF Yield | -46.54% | -2.58% | -9.81% | -5.63% |
| EV / EBITDA | -3.19 | 20.23 | -3.20 | -5.71 |
| Quality | ||||
| ROIC | -391.19% | -18.89% | -413.73% | -18.49% |
| Gross Margin | -246.43% | 97.15% | 71.00% | -3.62% |
| Cash Conversion Ratio | 1.53 | -0.47 | 0.77 | 1.78 |
| Growth | ||||
| Revenue 3-Year CAGR | -51.80% | 1.23% | 109.99% | 20.71% |
| Free Cash Flow Growth | -475.81% | -42.90% | 11.61% | 69.90% |
| Safety | ||||
| Net Debt / EBITDA | 0.32 | 0.68 | -0.18 | -0.01 |
| Interest Coverage | -32.41 | -5.61 | -142.99 | -527.31 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,399.79 | -2,345.62 | -357.89 | -353.84 |